125 related articles for article (PubMed ID: 12642691)
21. A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy.
Imanishi R; Ohtsuru A; Iwamatsu M; Iioka T; Namba H; Seto S; Yano K; Yamashita S
J Clin Endocrinol Metab; 2002 Oct; 87(10):4821-4. PubMed ID: 12364480
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: p53 as a sensor of transcriptional integrity.
Blagosklonny MV; Demidenko ZN; Fojo T
Cell Cycle; 2002 Jan; 1(1):67-74. PubMed ID: 12429911
[TBL] [Abstract][Full Text] [Related]
23. Functional and gene expression analysis of the p53 signaling pathway in clear cell sarcoma of the kidney and congenital mesoblastic nephroma.
Brownlee NA; Hazen-Martin DJ; Garvin AJ; Re GG
Pediatr Dev Pathol; 2002; 5(3):257-68. PubMed ID: 12007018
[TBL] [Abstract][Full Text] [Related]
24. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells.
Mori N; Matsuda T; Tadano M; Kinjo T; Yamada Y; Tsukasaki K; Ikeda S; Yamasaki Y; Tanaka Y; Ohta T; Iwamasa T; Tomonaga M; Yamamoto N
J Virol; 2004 May; 78(9):4582-90. PubMed ID: 15078940
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin restores p53 function and enhances the radiosensitivity in HPV16 E6 containing SiHa cells.
Huang H; Huang SY; Chen TT; Chen JC; Chiou CL; Huang TM
J Cell Biochem; 2004 Mar; 91(4):756-65. PubMed ID: 14991767
[TBL] [Abstract][Full Text] [Related]
26. A novel p53 mutant retained functional activity in lung carcinomas.
Ko JL; Chiao MC; Chang SL; Lin P; Lin JC; Sheu GT; Lee H
DNA Repair (Amst); 2002 Sep; 1(9):755-62. PubMed ID: 12509279
[TBL] [Abstract][Full Text] [Related]
27. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation.
Koumenis C; Alarcon R; Hammond E; Sutphin P; Hoffman W; Murphy M; Derr J; Taya Y; Lowe SW; Kastan M; Giaccia A
Mol Cell Biol; 2001 Feb; 21(4):1297-310. PubMed ID: 11158315
[TBL] [Abstract][Full Text] [Related]
28. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
Sánchez-Beato M; Piris MA; Martínez-Montero JC; García JF; Villuendas R; García FJ; Orradre JL; Martínez P
J Pathol; 1996 Sep; 180(1):58-64. PubMed ID: 8943816
[TBL] [Abstract][Full Text] [Related]
29. Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer.
Murakami J; Asaumi J; Kawai N; Tsujigiwa H; Yanagi Y; Nagatsuka H; Inoue T; Kokeguchi S; Kawasaki S; Kuroda M; Tanaka N; Matsubara N; Kishi K
Cancer Chemother Pharmacol; 2005 Jul; 56(1):22-8. PubMed ID: 15791453
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity.
Blagosklonny MV; Robey R; Sackett DL; Du L; Traganos F; Darzynkiewicz Z; Fojo T; Bates SE
Mol Cancer Ther; 2002 Sep; 1(11):937-41. PubMed ID: 12481415
[TBL] [Abstract][Full Text] [Related]
31. Effects of demethylating agent 5-aza-2(')-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines.
Murakami J; Asaumi J; Maki Y; Tsujigiwa H; Kuroda M; Nagai N; Yanagi Y; Inoue T; Kawasaki S; Tanaka N; Matsubara N; Kishi K
Oral Oncol; 2004 Jul; 40(6):597-603. PubMed ID: 15063388
[TBL] [Abstract][Full Text] [Related]
32. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein.
Takimoto R; Wang W; Dicker DT; Rastinejad F; Lyssikatos J; el-Deiry WS
Cancer Biol Ther; 2002; 1(1):47-55. PubMed ID: 12174820
[TBL] [Abstract][Full Text] [Related]
33. Limited role of N-terminal phosphoserine residues in the activation of transcription by p53.
Jackson MW; Agarwal MK; Agarwal ML; Agarwal A; Stanhope-Baker P; Williams BR; Stark GR
Oncogene; 2004 May; 23(25):4477-87. PubMed ID: 15064747
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
Rokhlin OW; Glover RB; Guseva NV; Taghiyev AF; Kohlgraf KG; Cohen MB
Mol Cancer Res; 2006 Feb; 4(2):113-23. PubMed ID: 16513842
[TBL] [Abstract][Full Text] [Related]
35. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells.
Blagosklonny MV; Giannakakou P; Wojtowicz M; Romanova LY; Ain KB; Bates SE; Fojo T
J Clin Endocrinol Metab; 1998 Jul; 83(7):2516-22. PubMed ID: 9661637
[TBL] [Abstract][Full Text] [Related]
36. Abundant expression of spliced HDM2 in Hodgkin lymphoma cells does not interfere with p14(ARF) and p53 binding.
Stürzenhofecker B; Schlott T; Quentin T; Kube D; Jung W; Trümper L
Leuk Lymphoma; 2003 Sep; 44(9):1587-96. PubMed ID: 14565663
[TBL] [Abstract][Full Text] [Related]
37. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.
Sasakawa Y; Naoe Y; Noto T; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
Biochem Pharmacol; 2003 Sep; 66(6):897-906. PubMed ID: 12963476
[TBL] [Abstract][Full Text] [Related]
38. Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in p53+/- and p53+/+ mice.
Wei M; Wanibuchi H; Morimura K; Salim EI; Moku M; Doi K; Mitsuhashi M; Masuda C; Shen J; Kinoshita A; Fukushima S
Anticancer Res; 2004; 24(2B):785-90. PubMed ID: 15161027
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
40. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
Piovesan B; Pennell N; Berinstein NL
Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
